Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Eravacycline Compared With Meropenem in Complicated Intra-abdominal Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female participant hospitalized for cIAI~* At least 18 years of age~* Evidence of a systemic inflammatory response~* Abdominal pain or flank pain (with or without rebound tenderness), or pain caused by cIAI that is referred to another anatomic area~* Able to provide informed consent~* If male: must agree to use an effective barrier method of contraception during the study and for 14 days following the last dose if sexually active with a female of childbearing potential~* If female, not pregnant or nursing or, if of childbearing potential: either will commit to use at least two medically accepted, effective methods of birth control (for example, condom, oral contraceptive, indwelling intrauterine device, hormonal implant /patch, injections, approved cervical ring) during study drug dosing and for 14 days following last study drug dose or practicing sexual abstinence~Exclusion Criteria:~* Unlikely to survive the 6-8 week study period~* Creatinine clearance of ≤50 milliliter (mL)/minute~* Presence or possible signs of significant hepatic disease~* Immunocompromised condition, including known human immunodeficiency virus (HIV) positivity, transplant recipients, and hematological malignancy~* History of moderate or severe hypersensitivity reactions to tetracyclines, carbapenems, β-lactam antibiotics, or to any of the excipients contained in the study drug formulations~* Participation in any investigational drug or device study within 30 days prior to study entry~* Known or suspected current central nervous system (CNS) disorder that may predispose to seizures or lower seizure threshold (for example, severe cerebral arteriosclerosis, epilepsy)~* Antibiotic-related exclusions:~  1. Receipt of effective antibacterial drug therapy for cIAI for a continuous duration of \>24-hours during the 72-hours preceding randomization \[however, participants with documented cIAI (that is, known baseline pathogen) who have received at least 72-hours of antibiotic therapy and are considered treatment failures may be enrolled. Treatment failure is defined as persistent fever and/or clinical symptoms; or the development of a new intra-abdominal abscess after ≥72-hours of antibiotic therapy\], or~ 2. Receipt of meropenem or any other carbapenem, or tigecycline for the current infection, or~ 3. Need for concomitant systemic antimicrobial agents effective in cIAI other than study drug~* Refusal of mechanical ventilation, dialysis or hemofiltration, cardioversion, or any other resuscitative measures and drug/fluid therapy at time of consent~* Known or suspected inflammatory bowel disease or associated visceral abscess~* The anticipated need for systemic antibiotics for a duration of more than 14 days~* Systemic malignancy that required chemotherapy, immunotherapy, radiation therapy, or antineoplastic therapy within the previous 3 months or that is anticipated to begin prior to the Test-of-Cure (TOC) visit~* Known at study entry to have cIAI caused by a pathogen(s) resistant to one of the study drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Eravacycline (Type: EXPERIMENTAL): None
- Meropenem (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).